Pacira's long-acting non-opioidpain drug gets FDA ok

 
• By Nancy Faigen
  
Generate a summary of this article
Listen to this article
Beta

The US FDA has cleared for marketing Pacira Pharmaceuticals' long-acting version of bupivacaine, Exparel (bupivacaine extended-release liposome injection), as a postsurgical analgesic. Although the stock hit a high of $11.10 as investors awaited word on FDA approval, the company must still spend considerable time and resources to gain acceptance of the product by hospitals, which have relied on conventionally released bupivacaine. Pacira's shares closed down 4% to $9.78 on 31 October.

The US FDA has cleared for marketing Pacira Pharmaceuticals' long-acting version of bupivacaine, Exparel (bupivacaine extended-release liposome injection), as a postsurgical analgesic. Although the stock hit a high of $11.10 as investors awaited word on FDA approval, the company must still spend considerable time and resources to gain acceptance of the product by hospitals, which have relied on conventionally released bupivacaine. Pacira's shares closed down 4% to $9.78 on 31 October.

The Parsippany, New Jersey-based firm is making preparations for a January 2012 launch, and has pegged much of its future...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By Saba Afreen

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.